Cipla Current Affairs, GK & News

Zydus Cadila launched the cheapest generic version of Remdesivir in India

August 13, 2020

Zydus Cadila launched the cheapest generic version of Gilead Sciences’ antiviral drug Remdesivir in India to treat the deadly COVID 19 pandemic. The version has been launched after reports of a shortage of the drugs in the hospitals of the country. The price of drugs has been fixed as Rs 2800 per 100 mg vial. ..

Month: 

Category: 

Topics:  • • • • • •

Cipla’s ‘Cipremi’ gets approval for Treatment of COVID-19 Patients in India

June 22, 2020

In its June 13th, 2020 guidelines for Clinical Management Protocol for COVID-19, the Union Health Ministry as a part of investigational therapy added ‘Remdesivir’ only for restricted emergency use. A week after, on 21st June 2020, Hetero and Cipla Pharmaceuticals were granted approval by the Drug Controller General of India for the production and marketing ..

Month: 

Category: 

Topics:  • • • • • • • •

Cipla acquires two US generic drug companies

February 19, 2016

Indian pharmaceutical giant Cipla Ltd. has acquired two US generic drug companies, InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc. In this regard, Cipla has closed the transaction of the deal through its wholly-owned subsidiary, Cipla (EU) Ltd. Key facts These deals will allow Cipla to further strengthen its presence in the US pharmaceutical market is ..

Month: 

Topics:  • • • • •

Cipla wins Rs 1170 cr tender from Global Fund to supply HIV drugs

February 13, 2015

Indian pharmaceutical giant, Cipla has been awarded $188.95 million (around Rs. 1,172 crore) Contract by Global Fund to supply ARV (anti-retroviral) drugs. Cipla has been selected as a Panel Supplier for a supplier partnership agreement. This contract is effective from 1 January 2015 and will run for a period of three years i.e. till 2018. ..

Month: 

Topics:  • • •